Zoetis (ZTS) Stock Price, News & Analysis

Company Overview

Zoetis Inc. (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company's offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering. Since becoming independent, the company has expanded its capabilities through internal research and development and strategic acquisitions, broadening its diagnostics, biotechnology and product pipelines. Its product portfolio spans both companion animal brands and large-animal solutions, and it also provides technical services, training and digital tools intended to help veterinarians and producers manage herd health and clinical decisions.

Headquartered in Parsippany, New Jersey, Zoetis operates globally with commercial and manufacturing presence across North America, Europe, Latin America and the Asia Pacific region, serving customers in numerous international markets. The company is led by a senior management team focused on innovation, regulatory compliance and expanding access to animal health solutions; Kristin Peck serves as Chief Executive Officer. Zoetis emphasizes investment in research, manufacturing capabilities and partnerships to address evolving animal-health challenges and support food security, animal welfare and the veterinary profession.

Key Stats

• Today's Range: $77.25 to $80.44
• 50-Day Range: $74.11 to $122.69
• 52-Week Range: $72.38 to $172.23
• Volume: 7.40 million shs
• Average Volume: 8.46 million shs
• Market Capitalization: $33.39 billion
• P/E Ratio: 13.21
• Dividend Yield: 2.66%
• Price Target: $134.75
• Consensus Rating: Hold

Zoetis Stock Analysis - MarketRank™

Zoetis scored higher than 100% of companies evaluated by MarketBeat, and ranked 1st out of 856 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.2 / 5
• Analyst Rating: Hold

Consensus Rating

Zoetis has received a consensus rating of Hold. The company's average rating score is 2.40, and is based on no strong buy ratings, 7 buy ratings, 7 hold ratings, and 1 sell rating.

Upside Potential

Zoetis has a consensus price target of $134.75, representing about 69.2% upside from its current price of $79.64.

Amount of Analyst Coverage

Zoetis has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 2.5 / 5
• Proj. Earnings Growth: 7.85%

Earnings Growth

Earnings for Zoetis are expected to grow by 7.85% in the coming year, from $6.88 to $7.42 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Zoetis is 13.21, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 44.53.

Price to Earnings Ratio vs. Sector

The P/E ratio of Zoetis is 13.21, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 20.82.

Price to Earnings Growth Ratio

Zoetis has a PEG Ratio of 1.29. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

Zoetis has a P/B Ratio of 10.33. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

3.54% of the float of Zoetis has been sold short.

Short Interest Ratio / Days to Cover

Zoetis has a short interest ratio ("days to cover") of 3.81, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Zoetis has recently increased by 9.62%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 4.2 / 5
• Dividend Strength: Strong

Dividend Yield

Zoetis pays a meaningful dividend of 2.69%, higher than the bottom 25% of all stocks that pay dividends.

Dividend Growth

Zoetis has been increasing its dividend for 14 years.

Dividend Coverage

The dividend payout ratio of Zoetis is 35.16%. This payout ratio is at a healthy, sustainable level, below 75%.

Dividend Sustainability

Based on earnings estimates, Zoetis will have a dividend payout ratio of 28.57% next year. This indicates that Zoetis will be able to sustain or increase its dividend.

News and Social Media

• Score: 4.2 / 5
• News Sentiment: 0.71

News Sentiment

Zoetis has a news sentiment score of 0.71. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.38 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 33 news articles for Zoetis this week, compared to 11 articles on an average week.

Search Interest

77 people have searched for ZTS on MarketBeat in the last 30 days. This is an increase of 221% compared to the previous 30 days.

MarketBeat Follows

15 people have added Zoetis to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 3.6 / 5
• Insider Trading: Acquiring Shares

Cluster Insider Buying

3 insiders have purchased shares of Zoetis in the last three months. Multiple insiders buying is a strong bullish signal.

Net Insider Buying

Over the last three months, insiders have purchased a net $886,384.00 in company stock, which represents 0.0027% of the company's market cap.

Insider Buying vs. Insider Selling

In the past three months, Zoetis insiders have bought more of their company's stock than they have sold. Specifically, they have bought $886,384.00 in company stock and sold $0.00 in company stock.

Percentage Held by Insiders

0.22% of the stock of Zoetis is held by insiders.

Percentage Held by Institutions

92.80% of the stock of Zoetis is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Record date for 3/3 Dividend: 1/20/2026
• Ex-Dividend for 3/3 Dividend: 1/20/2026
• Dividend Payable: 3/03/2026
• Record date for 6/2 Dividend: 4/20/2026
• Ex-Dividend for 6/2 Dividend: 4/20/2026
• Last Earnings: 5/07/2026
• Today: 5/21/2026
• Dividend Payable: 6/02/2026
• Next Earnings (Estimated): 8/04/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: Pharmaceuticals
• Current Symbol: NYSE:ZTS
• CIK: 1555280
• Web: www.zoetis.com
• Phone: (973) 822-7000
• Fax: 302-655-5049
• Employees: 14,500
• Year Founded: 1952

Price Target and Rating

• Average Price Target for Zoetis: $134.75
• High Price Target: $190.00
• Low Price Target: $99.00
• Potential Upside/Downside: +69.2%
• Consensus Rating: Hold
• Rating Score (0-4): 2.40
• Research Coverage: 15 Analysts

Profitability

• EPS (Trailing Twelve Months): $6.03
• Trailing P/E Ratio: 13.21
• Forward P/E Ratio: 11.58
• P/E Growth: 1.29
• Net Income: $2.67 billion
• Net Margins: 27.80%
• Pretax Margin: 35.18%
• Return on Equity: 66.85%
• Return on Assets: 18.79%

Debt

• Debt-to-Equity Ratio: 2.80
• Current Ratio: 3.15
• Quick Ratio: 1.91

Sales & Book Value

• Annual Sales: $9.47 billion
• Price / Sales: 3.53
• Cash Flow: $7.64 per share
• Price / Cash Flow: 10.43
• Book Value: $7.71 per share
• Price / Book: 10.33

Miscellaneous

• Outstanding Shares: 419,230,000
• Free Float: 418,306,000
• Market Cap: $33.39 billion
• Optionable: Optionable
• Beta: 0.87